Carbowhite

Phase 2Small molecule

OOmnifarma Kiev LLC

Carbowhite is one of 14 small molecule programs targeting Acute Diarrhea. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute DiarrheaActive, not recruiting

Acute DiarrheaPhase 2

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Acute Diarrhea

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Approved

1 2

Azulfidine

Pfizer

Phase 3

1 3

Bacillus Clausii

Sanofi

Approved

1 4

Galzin

AAmerican Regent, Inc.

Phase 3

1 5

Oral Anti-Diabetic Drugs

Sanofi

Approved

1 6

Zinc Sulphate

IInternational Centre for Diarrhoeal Disease Research, Bangladesh

Phase 3

1 7

Standard DAPT Duration

FFederico II University

Approved

1 8

Loperamide Hydrochloride

Johnson & Johnson

Phase 3

1 9

Racecadotril

MMcNeil AB

Phase 3

1 10

Racecadotril Plus ORS

AAbbott

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Diarrhea1 trial

Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea

Completed·OOmnifarma Kiev LLC·Phase 2·NCT03633344·145 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carbowhite. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carbowhite compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carbowhite. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Omnifarma Kiev LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOmnifarma Kiev LLC

Carbowhite

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Diarrhea1 trial

References

Drug Info

Quick Facts

Related News